These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 26672362)

  • 21. From "magic bullets" to specific cancer immunotherapy.
    Riether C; Schürch C; Ochsenbein AF
    Swiss Med Wkly; 2013; 143():w13734. PubMed ID: 23348718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-targeted immunotherapy for treatment of malignancy.
    White CA; Weaver RL; Grillo-López AJ
    Annu Rev Med; 2001; 52():125-45. PubMed ID: 11160771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy.
    De Santis R
    MAbs; 2020; 12(1):1725346. PubMed ID: 32054397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
    Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
    Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Progress of study on antitumor effects of antibody dependent cell mediated cytotoxicity--review].
    Qu YH; Li Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1370-5. PubMed ID: 21129296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody engineering: facing new challenges in cancer therapy.
    Sanz L; Cuesta AM; Compte M; Alvarez-Vallina L
    Acta Pharmacol Sin; 2005 Jun; 26(6):641-8. PubMed ID: 15916728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [An overview of antibody-based cancer therapy].
    Miao QF; Shao RG; Zhen YS
    Yao Xue Xue Bao; 2012 Oct; 47(10):1261-8. PubMed ID: 23289136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody-Based Cancer Therapy: Successful Agents and Novel Approaches.
    Hendriks D; Choi G; de Bruyn M; Wiersma VR; Bremer E
    Int Rev Cell Mol Biol; 2017; 331():289-383. PubMed ID: 28325214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer immunotherapy of targeting angiogenesis.
    Hou J; Tian L; Wei Y
    Cell Mol Immunol; 2004 Jun; 1(3):161-6. PubMed ID: 16219162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-drug conjugates: an emerging concept in cancer therapy.
    Chari RV; Miller ML; Widdison WC
    Angew Chem Int Ed Engl; 2014 Apr; 53(15):3796-827. PubMed ID: 24677743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modern Immunotherapy for the Treatment of Advanced Gastrointestinal Cancers.
    Khalil DN; Segal NH
    Oncology (Williston Park); 2016 Jan; 30(1):85-90, 93. PubMed ID: 26791849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paul Ehrlich's magic bullet concept: 100 years of progress.
    Strebhardt K; Ullrich A
    Nat Rev Cancer; 2008 Jun; 8(6):473-80. PubMed ID: 18469827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody therapeutics in cancer.
    Sliwkowski MX; Mellman I
    Science; 2013 Sep; 341(6151):1192-8. PubMed ID: 24031011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment.
    Koster BD; de Gruijl TD; van den Eertwegh AJ
    Curr Opin Oncol; 2015 Nov; 27(6):482-8. PubMed ID: 26352539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nature's best weapons to fight cancer. Revival of human monoclonal IgM antibodies.
    Vollmers HP; Brändlein S
    Hum Antibodies; 2002; 11(4):131-42. PubMed ID: 12775893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antibody-dependent cellular cytotoxicity in the immunotherapeutic mechanisms of anti-EGFR monoclonal antibody].
    Shimodaira H; Komine K; Soeda H; Ishioka C
    Gan To Kagaku Ryoho; 2010 May; 37(5):795-8. PubMed ID: 20495309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal antibody therapy for solid tumors.
    Green MC; Murray JL; Hortobagyi GN
    Cancer Treat Rev; 2000 Aug; 26(4):269-86. PubMed ID: 10913382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.